Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 12/20 | 0.56 |
| ▸ | TYMS | P04818 | 7/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.47 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.47 |
| ▸ | GART | P22102 | 1/20 | 0.47 |
| ▸ | ATIC | P31939 | 1/20 | 0.47 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.47 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.47 |
| ▸ | FRK | P42685 | 1/20 | 0.47 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12559669 | 0.87 | DHFR (0.64) | DHFRTYMSNAMPTFOLR2FOLR1 | |
| SCHEMBL12616064 | 0.87 | DHFR (0.64) | DHFRTYMSNAMPTFOLR2FOLR1 | |
| SCHEMBL12559684 | 0.84 | DHFR (0.63) | DHFRTYMSNAMPTFOLR2FOLR1 | |
| SCHEMBL12616333 | 0.84 | DHFR (0.55) | DHFRTYMSNAMPTFOLR2FOLR1 | |
| SCHEMBL12597980 | 0.84 | DHFR (0.55) | DHFRTYMSNAMPTFOLR2FOLR1 | |
| SCHEMBL13971 | 0.82 | DHFR (0.63) | DHFRTYMSNAMPTFOLR2FOLR1 | |
| SCHEMBL1801501 | 0.82 | DHFR (0.63) | DHFRTYMSNAMPTFOLR2FOLR1 | |
| SCHEMBL1798854 | 0.81 | DHFR (0.62) | DHFRTYMSNAMPTFOLR2FOLR1 | |
| SCHEMBL1798861 | 0.81 | DHFR (0.62) | DHFRTYMSNAMPTFOLR2FOLR1 | |
| SCHEMBL1798857 | 0.81 | TYMS (0.56) | DHFRTYMSNAMPTFOLR2FOLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152276-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES AS ANTIFOLATES | Chelsea Thereapeutics, Inc. | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152276-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES AS ANTIFOLATES | CCR9, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNO | DHFR 105/4885TYMS 154/4885NAMPT 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.